Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

ABCB1 and ABCC2 and the risk of distant metastasis in Thai breast cancer patients treated with tamoxifen.

Sensorn I, Sukasem C, Sirachainan E, Chamnanphon M, Pasomsub E, Trachu N, Supavilai P, Pinthong D, Wongwaisayawan S.

Onco Targets Ther. 2016 Apr 12;9:2121-9. doi: 10.2147/OTT.S100905. eCollection 2016.

2.

Polymorphism at 19q13.41 Predicts Breast Cancer Survival Specifically after Endocrine Therapy.

Khan S, Fagerholm R, Rafiq S, Tapper W, Aittomäki K, Liu J, Blomqvist C, Eccles D, Nevanlinna H.

Clin Cancer Res. 2015 Sep 15;21(18):4086-96. doi: 10.1158/1078-0432.CCR-15-0296. Epub 2015 May 11.

3.

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen.

de Vries Schultink AH, Zwart W, Linn SC, Beijnen JH, Huitema AD.

Clin Pharmacokinet. 2015 Aug;54(8):797-810. doi: 10.1007/s40262-015-0273-3. Review.

4.

Pharmacogenetics of SULT1A1.

Daniels J, Kadlubar S.

Pharmacogenomics. 2014 Nov;15(14):1823-1838.

5.

Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen.

Markopoulos C, Kykalos S, Mantas D.

World J Clin Oncol. 2014 Aug 10;5(3):374-81. doi: 10.5306/wjco.v5.i3.374. Review.

6.

The effects of a novel hormonal breast cancer therapy, endoxifen, on the mouse skeleton.

Gingery A, Subramaniam M, Pitel KS, Reese JM, Cicek M, Lindenmaier LB, Ingle JN, Goetz MP, Turner RT, Iwaniec UT, Spelsberg TC, Hawse JR.

PLoS One. 2014 May 22;9(5):e98219. doi: 10.1371/journal.pone.0098219. eCollection 2014.

7.

Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy.

Cronin-Fenton DP, Damkier P, Lash TL.

Future Oncol. 2014 Jan;10(1):107-22. doi: 10.2217/fon.13.168. Review.

8.

Tamoxifen resistance in breast cancer.

Chang M.

Biomol Ther (Seoul). 2012 May;20(3):256-67. doi: 10.4062/biomolther.2012.20.3.256. Review.

9.

CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis.

Lum DW, Perel P, Hingorani AD, Holmes MV.

PLoS One. 2013 Oct 2;8(10):e76648. doi: 10.1371/journal.pone.0076648. eCollection 2013. Review.

10.

Frequencies of Functional Polymorphisms in Three Pharmacokinetic Genes of Clinical Interest within the Admixed Puerto Rican Population.

Orengo-Mercado C, Nieves B, López L, Vallés-Ortiz N, Renta JY, Santiago-Borrero PJ, Cadilla CL, Duconge J.

J Pharmacogenomics Pharmacoproteomics. 2013 Mar 27;4(113). pii: 1000113.

11.

Phase two steroid metabolism and its roles in breast and prostate cancer patients.

McNamara KM, Nakamura Y, Miki Y, Sasano H.

Front Endocrinol (Lausanne). 2013 Sep 4;4:116. doi: 10.3389/fendo.2013.00116. Review.

12.

Sulfotransferase genetic variation: from cancer risk to treatment response.

Daniels J, Kadlubar S.

Drug Metab Rev. 2013 Nov;45(4):415-22. doi: 10.3109/03602532.2013.835621. Epub 2013 Sep 6. Review.

13.

PharmGKB summary: tamoxifen pathway, pharmacokinetics.

Klein DJ, Thorn CF, Desta Z, Flockhart DA, Altman RB, Klein TE.

Pharmacogenet Genomics. 2013 Nov;23(11):643-7. doi: 10.1097/FPC.0b013e3283656bc1. Review. No abstract available.

14.

Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen.

Chamnanphon M, Pechatanan K, Sirachainan E, Trachu N, Chantratita W, Pasomsub E, Noonpakdee W, Sensorn I, Sukasem C.

Pharmgenomics Pers Med. 2013 May 24;6:37-48. doi: 10.2147/PGPM.S42330. Print 2013.

15.

Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study.

Brooks JD, Teraoka SN, Malone KE, Haile RW, Bernstein L, Lynch CF, Mellemkjær L, Duggan DJ, Reiner AS, Concannon P, Schiermeyer K, Lewinger JP; WECARE Study Collaborative Group, Bernstein JL, Figueiredo JC.

Int J Mol Epidemiol Genet. 2013;4(1):35-48. Epub 2013 Mar 18.

16.

Functional polymorphisms in xenobiotic metabolizing enzymes and their impact on the therapy of breast cancer.

Vianna-Jorge R, Festa-Vasconcellos JS, Goulart-Citrangulo SM, Leite MS.

Front Genet. 2013 Jan 22;3:329. doi: 10.3389/fgene.2012.00329. eCollection 2012.

17.

Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management.

Rofaiel S, Muo EN, Mousa SA.

Pharmgenomics Pers Med. 2010;3:129-43. doi: 10.2147/PGPM.S10789. Epub 2010 Sep 17.

18.

SULT1A1 rs9282861 polymorphism-a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer?

Tengström M, Mannermaa A, Kosma VM, Hirvonen A, Kataja V.

BMC Cancer. 2012 Jun 18;12:257. doi: 10.1186/1471-2407-12-257.

19.

The Discriminatory Value of CYP2D6 Genotyping in Predicting the Dextromethorphan/Dextrorphan Phenotype in Women with Breast Cancer.

Trojan A, Vergopoulos A, Breitenstein U, Seifert B, Rageth C, Joechle W.

Breast Care (Basel). 2012 Feb;7(1):25-31. Epub 2012 Feb 20.

20.

Tamoxifen and CYP2D6: a contradiction of data.

Hertz DL, McLeod HL, Irvin WJ Jr.

Oncologist. 2012;17(5):620-30. doi: 10.1634/theoncologist.2011-0418. Epub 2012 Apr 24. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk